Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 59

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 59
---
akeda announced that it received approval from the European Commission (EC).

(5) Partnership with Protagonist Therapeutics. Protagonist leads development.

(6) Partnership with Keros Therapeutics, Inc.

(7) Elritercept MDS trial actively recruiting

(8) Partnership with AbbVie. Global P-III trial in platinum-sensitive ovarian cancer is led by AbbVie.

Table of Contents

Other Rare Diseases programs

Takeda’s R& D engine is focused on areas of high unmet medical need, both in rare and more prevalent conditions, across three core therapeutic areas (gastrointestinal and inflammation, neuroscience and oncology). In other Rare Diseases programs, Takeda focuses on several areas of high unmet medical need, on top of marketed products such as TAKHZYRO in hereditary angioedema. In rare hematology, Takeda focuses on addressing today’s needs in the treatment of bleeding disorders, including through ADVATE and ADYNOVATE/ADYNOVI. In addition, Takeda aims to redefine the management of post-transplant cytomegalovirus (CMV) infection/disease with LIVTENCITY. Takeda commits to fulfilling our vision to deliver life-transforming medicines to patients with rare diseases. Takeda will continue to explore late-stage business development that may leverage our rare diseases capabilities as well as bolster our commitment and leadership in rare diseases.

Our other rare diseases pipeline in clinical development as of May 8, 2025 (the date of our annual earnings release), along with notes for major subsequent developments thereafter, is as follows:

  Development code           Type of Drug                                         Modality                Indications / additional formulations                                                                          Country/Region      Stage                
  TAK-620 1                  Benzimidazole riboside inhibitor (oral)              Small molecule          Post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies      Japan               Approved (Jun 2024)  
                                                                                                          Treatment of children and teenage transplant recipients with CMV infection                                     Global              P-III                
  TAK-577                    von Willebrand factor [recombinant] (injection)      Biologic and other      Adult on-demand and surgery treatment of                                                                       China               Approved (Aug 2024)  
                                                                                                          Pediatric on-demand and surgery treatment of                                                                   Global              P-III 2              
                                                                                                          Pediatric prophylaxis treatment of von Willebrand